Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- Alzheimerâ€™s disease
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 239034
(a) First US provisional filed January 22, 2001 (60/262,651).
(b) Second US provisional filed February 8, 2001 (60/267,196).
(c) Third US provisional filed July 19, 2001 (60/306,140)
(d) A regular US patent application (10/051,309) was filed on January 22, 2002, claiming priority to the above-mentioned three US provisional applications.
(a) First US provisional filed February 8, 2001 (60/267,195)
(b) Second US provisional filed January 7, 2002 (60/344,824).
(c) A regular US patent application (10/067,996) was filed on February 8, 2002, claiming priority to the above-mentioned two US provisional applications.
(d) Possible Second US family to be filed; awaiting analysis from MPC.
A first US provisional application (Memory 3 VI) was filed October 16, 2001 (60/329,314).
(a) First US provisional filed November 15, 2001 (60/331,422)
(b) Second US provisional filed January 23, 2002 (60/349,985).
(a) U.S. provisional application filed June 25, 1999 (60/141,196
(b) A regular U.S. Patent Application was filed June 23, 2000 (09/602,735), claiming priority to the above-mentioned provisional application.
Licensor Compound means any PDE4 inhibitor for which Licensor either prior to the Effective Date or during the Agreement Term has rights, whether by reason of its own conception of such inhibitor, or under agreement with a Third Party.
Collaboration Compound means any PDE4 inhibitor that (i) either or both Parties or its Affiliates conceives in the conduct of the Research Collaboration, or (ii) the JLT otherwise agrees shall constitute a Collaboration Compound pursuant to the Research Workplan.
'Neurological Indication' means prophylaxis or treatment of Alzheimers' disease, prophylaxis or treatment of mild cognitive impairment ('MCI') or treatment of vascular dementia.
'Non-Memory Compound' means a PDE4 inhibitor, other than a Memory Compound or a Collaboration Compound, with respect to which the initial IND for the inhibitor is for a Neurological Indication or Psychiatric Indication.
'Psychiatric Indication' means depression, anxiety or mixed anxiety/depression.
MEM 1917 is a PDE4 inhibitor that we are developing for the treatment of depression.
IPSCIO Record ID: 203518
Under the Amendment, the Licensor has reacquired from Licensee the right to develop and commercialize the PDE4 inhibitors MEM 1414 and MEM 1917, each an Option Compound and collectively, the Option Compounds, alone or with a third party. Licensee has an option, exercisable following the completion of Phase II clinical trials for each of the Option Compounds, to continue that Option Compoundâ€™s development and commercialization. If Licensee does not exercise its option with respect to an Option Compound, then Licensee shall have no further rights or interest with respect to that Option Compound.
Licensee maintains exclusive License to Other PDE4 Inhibitors under the Collaboration.
Licensee shall assign and transfer to Licensor at no expense to Licensor the items set forth in the Agreement solely to the extent each relates to MEM 1414 and MEM 1917, free and clear of any liens or security interests; create a shareweb of the items set forth for use by both Parties as reference data, and transfer existing inventory of MEM 1414 and MEM 1917 to Licensor at no expense to Licensor, free and clear of any liens or security interests. Licensees obligations of the Agreement shall be fulfilled and discharged by Licensees transfer of existing inventory of MEM 1414 and MEM 1917 to Licensor as provided herein.
Licensee shall have the Option to obtain an exclusive license to develop and commercialize MEM 1414 and/or MEM 1917, each an Option Compound.
If Licensee exercises the Option with respect to an Option Compound, then such Option Compound shall be deemed to be a Licensor Compound for purposes of the Agreement, and all provisions of the Agreement shall apply to such Option Compound, except for those provisions that are changed by this Second Amendment.
The Option Compounds are PDE4 inhibitors MEM 1414 and MEM 1917.
IPSCIO Record ID: 291160
Patent Right means all rights under any patent or patent application in any country of the Territory, including any substitution, extension or supplementary protection certificate, reissue, reexamination, renewal, division, continuation or continuations-in-part thereof.
Collaboration Compound means any PDE4 inhibitor that (i) either or both Parties or their Affiliates conceive in the conduct of the Research Collaboration, (ii) Memory has rights to under an agreement with a Third Party as of the Effective Date, (iii) the JLT otherwise agreed shall constitute a Collaboration Compound pursuant to the Research Workplan, or (iv) Memory conceived prior to the date of the Original Agreement. All Collaboration Compounds identified as of the Effective Date are set forth in Schedule I hereto.
Compounds active as PDE4 inhibitors, including a compound known as MEM1414.
The parties entered into a collaboration to develop MEM1414 for commercialization; develop potential back-up compounds and other PDE4 inhibitors focused on central nervous system indications; and explore potential applications for other therapeutic areas such as respiratory disease.
IPSCIO Record ID: 299222
Psychiatric Indication means schizophrenia, including management of the manifestations of symptoms of schizophrenia, depression, bipolar disorders, anxiety and ADHD.
IPSCIO Record ID: 274611
Licensor hereby also grants to Licensee an exclusive (even as to Licensor), royalty-free right and license in the Territory, with the right to grant sublicenses as part of any sublicense of rights granted with respect to Licensed Products, to use the Licensed Trademarks in connection with using, selling and offering for sale Licensed Products in the Territory in the Field during the Term.
(a) Patent applications (including provisional patent applications and PCT patent applications) or patents as follows
(i) U.S. Patent Application Serial No./U.S. Provisional Patent Application Serial No. 60/052,087(provisional), HHS Reference number E-247-1997/0, filed July 9, 1997, entitled Highly Selective Butyrylcholinestcrase Inhibitors for the Treatment and Diagnosis of Alzheimerâ€™s Disease and Dementias, and
(ii) U.S. Patent Application Serial No./U.S. Provisional Patent Application Serial No, 60/245,329 (provisional), HHS Reference number E-141-2000/0, filed November 2, 2000, entitled Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof, and any U.S. and foreign patent application(s) claiming the benefit of priority thereof including all divisions and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all these patents to the extent that at least one Inventor from the Institution is an Inventor thereon.
IPSCIO Record ID: 245875
BACE Collaboration Compound means a compound that is a BACE Inhibitor, and is discovered by either or both Parties or their Affiliates during the Research Term, or is acquired by either or both Parties or their Affiliates during the Research Term, or was discovered by Licensor prior to the Research Term. BACE Collaboration Compounds discovered prior to the Effective Date by Licensor.
BACE Inhibitor means a compound that at Licensor inhibits human BACE enzyme activity by fifty percent (50%) at a concentration (IC50) of less than one micromole per liter ( <l Âµmol/L) in an in vitro assay in which the Licensor inhibitor standard, I-!4848, has an ICso of less than fifteen nanomoles per liter (<15 nmoVL) in an assay following the protocol as currently performed at Vitae and/or a compound that at Licensee inhibits human BACE enzyme activity by fifty percent (50%) at an ICso of less than one micromole per liter (<l Âµmol/L) in in vitro assays in which the Licensee standard inhibitor, N-((1S,2R)-1-benzyl-3- cyclopropylamino-2-hydroxy-propyl)-5-(methanesulfonyl-methyl-amino )-N-( (R)-1-phenylethyl)-isophthalamide (compound 3 from Stachel et al. J. Med. Chem. 2004, 47, 6447-6450) has an IC50 of less than or equal to seventy nanomoles per liter (s70 nmol/L) in assays following the protocols as currently performed at Licensee.
Licensee is responsible for the development and commercialization of BACE inhibitors for the treatment of Alzheimer's disease and other forms of dementia.
IPSCIO Record ID: 344537
This agreement includes a non-exclusive grant back to Licensor.
Compounds means compounds that were or are identified, synthesized, discovered, designed or acquired by or on behalf of (A) Licensor or its Affiliates either prior to the date hereof or during the Term, (B) Licensee or its Affiliates during the term of the Research and Development Program, or (C) a Non-ND Partner or its Affiliates either prior to the date hereof or during the Term, but only if during the term of a Non-ND Research Program; either are HDAC Inhibitors or (b) are developed pursuant to the Collaboration (subject to the last sentence of this defined term Compound); possess certain basic drug characteristics and range of chemotypes with pan and sub-type selective HDAC inhibition characteristics, as mutually agreed to by the Parties from time to time; and are used or useful in the Field.
HDAC means HDAC Class I and HDAC Class II, collectively.
HDAC Inhibitors means Small Molecules that directly inhibit HDAC Class I or HDAC Class II enzymatic activity or which have therapeutic effect through the inhibition of HDAC Class I or HDAC Class II enzymes.
Licensor Program Compounds means the approximately(Â± 5%) 1014 Compounds.
Field means the treatment or prevention of Huntingtons disease, Parkinsons disease, Alzheimers disease, and the Other Neurodegenerative Diseases using an HDAC Inhibitor or any Compound developed pursuant to the Collaboration; provided, however, that the term Field shall cease to include ALS or Dementia if, as to a particular Subject Indication.
'Applicable Field' means the Field, but only as to the disease indications within the Research and Development Program that is the subject of a Back-Out (i.e., the AD R&D Program, the HD R&D Program or the PD R&D Program), in each case including any of the Other Neurodegenerative Diseases.